Current Headlines

  1. Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease 10/1/2025

    Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease.

  2. Pharming Group Announces U.S. FDA Acceptance And Priority Review Of Supplemental New Drug Application For Leniolisib In Children With APDS Aged 4 To 11 Years 10/1/2025

    Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

  3. Illumina Launches New Business To Accelerate Technology And Data-Driven Discovery 10/1/2025

    Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data.

  4. A New Analytical Tool To Optimize The Potency And Selectivity Of Drugs 9/30/2025

    Researchers at Baylor College of Medicine have developed a powerful new data analysis method named COOKIE-Pro (Covalent Occupancy Kinetic Enrichment via Proteomics) that provides a comprehensive, unbiased view of how a class of drugs, called covalent inhibitors, interacts with proteins throughout the cell.

  5. Disc Medicine Announces Submission Of New Drug Application (NDA) To US FDA For Accelerated Approval Of Bitopertin For Patients With Erythropoietic Protoporphyria (EPP) 9/30/2025

    Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bitopertin for patients aged 12 years and older with erythropoietic protoporphyria (EPP), including X-linked protoporphyria (XLP).

  6. TileDB, Kepler AI, And Tahoe Therapeutics Partner To Transform Single-Cell Data Analysis With AI-Powered Platform 9/30/2025

    TileDB, Inc., Kepler AI, and Tahoe Therapeutics today announced a groundbreaking partnership to create the first public-facing platform that enables researchers to run sophisticated AI agent-based queries on massive single-cell datasets at unprecedented scale.

  7. BioLineRx Ltd. And Hemispherian AS Establish Joint Venture To Develop GLIX1, A First-In-Class, Oral, Small Molecule Targeting DNA Damage Response In Glioblastoma And Other Cancers 9/29/2025

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a Norwegian biotech company focused on small molecule cancer therapeutics, today announced the establishment of a joint venture (JV) to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma (GBM) and other cancers.

  8. Concept Life Sciences Expands Integrated Drug Discovery Facilities 9/26/2025

    Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, today announces the official opening, by Jonathan Pearce, the Labour Member of Parliament for High Peak, of its expanded integrated drug discovery facilities at its Chapel-en-le-Frith site. This expansion brings chemistry, ADMET and screening biology capabilities together under one roof with 130 scientists now on site.

  9. Deep EigenMatics Receives United States Patent For Inventing Breakthrough Artificial Intelligence Method For Protein Design and Drug Discovery 9/26/2025

    Deep EigenMatics, a startup developing innovative Artificial Intelligence methods for drug discovery and development, has been awarded a United States Patent for a new breakthrough invention for AI-based drug discovery and protein design.

  10. SciSparc Resolves To Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative To Revolutionize AI Drug Discovery 9/25/2025

    SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”).